Adiposity Related Biomarkers and Breast Tumor Size

描述（申请人的描述）越来越多的报告 证实肥胖是复发和死亡的危险因素， 乳腺癌患者。 体重较重的女性复发的风险增加， 死亡，与较瘦的女性相比，即使在控制了其他预后因素后， 因素 我们假设，体重较大的女性， 肿瘤（最终预后更差）由于以下内分泌- 与肥胖相关的代谢激素， 乳腺癌快速增殖：瘦素、1型胰岛素样生长因子 胰岛素样生长因子结合蛋白3（IGFBP-3）， 胰岛素 IGF-1、IGFBP-3和胰岛素都与乳腺癌的发生有关。 癌症发病率和疾病存活率下降。 这些激素 直接或通过介导途径与肥胖相关（例如， 生长激素/IGF轴）。 瘦素水平与脂肪量高度相关。 最近，两项流行病学研究发现， 瘦素水平与乳腺癌发病率之间的关系。 一项基于人群的浸润性乳腺癌病例队列研究首次发现 通过两项关于年轻女性乳腺癌病因的大型研究， 对影响生存的因素的跟踪是潜在的 这个项目的基础设施。 关于参与者的广泛信息 收集，使用详细的问卷，广泛的医疗记录， 回顾，以及组织病理学回顾和肿瘤的分子分析。 从原始研究的参与者中收集血浆样本， 将用于完成感兴趣的激素的测定。 拟议 试点研究，将比较各组之间的激素水平， 年轻浸润性乳腺癌患者的肿瘤大小和体重指数（BMI） 例 还将检查激素水平与肿瘤的关系 预后标志物 目前迫切需要阐明潜在的生物学机制， 乳腺癌患者中与肥胖相关的不良预后。 这项研究的发现可以开始阐明肥胖的机制， 影响乳腺癌的预后

DESCRIPTION (Applicant's Description) An increasing number of reports substantiate that obesity is a risk factor for recurrence and mortality in breast cancer patients. Heavier women have an increased risk of recurrence or death, compared to thinner women, even after controlling for other prognostic factors. We hypothesize that women of greater body mass present with larger tumors (and ultimately a worse prognosis) due to the following endocrine- metabolizing hormones that are associated with obesity and that may mediate rapid breast tumor proliferation: leptin, type 1 insulin-like growth factor (IGF-1), insulin-like growth factor binding protein type 3 (IGFBP-3) and insulin. IGF-1, IGFBP-3 and insulin have all been associated with both increased breast cancer incidence and decreased survival from the disease. These hormones are associated with obesity either directly or through mediating pathways (e.g., growth hormone/IGF axis). Leptin levels are highly correlated with fat mass. Recently, two epidemiologic studies found a relationship between circulating leptin levels and breast cancer incidence. A population-based cohort of invasive breast cancer cases first identified through two large studies of breast cancer etiology in young women and now being followed for factors that affect survival serves as the underlying infrastructure for this project. Extensive information on participants has been collected, using detailed questionnaires, an extensive medical records review, as well as a histopathology review and molecular analysis of tumors. Plasma samples were collected from participants in the original studies and will be used to complete assays of the hormones of interest. For the proposed pilot study, a comparison will be made of hormone levels across groups defined by tumor size and body mass index (BMI) among young invasive breast cancer cases. Hormone levels will also be examined for their relationship with tumor prognostic markers. There is a critical need to elucidate possible biologic mechanisms underlying the poor prognosis associated with obesity in breast cancer patients. Findings from this study could begin to clarify a mechanism by which adiposity affects prognosis from breast cancer.